Shares of Pulse Biosciences, Inc (NASDAQ:PLSE – Get Free Report) have been assigned an average rating of “Moderate Buy” from the six analysts that are currently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, four have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month target price among brokers that have covered the stock in the last year is $45.25.
Several equities research analysts recently commented on PLSE shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Pulse Biosciences in a research report on Friday, July 17th. Needham & Company LLC started coverage on Pulse Biosciences in a report on Monday, August 17th. They issued a “buy” rating and a $58.00 price objective for the company. Freedom Capmkts raised Pulse Biosciences to a “strong-buy” rating in a research report on Wednesday, September 9th. Wall Street Zen raised Pulse Biosciences from a “sell” rating to a “hold” rating in a research note on Sunday, September 6th. Finally, Oppenheimer reiterated an “outperform” rating on shares of Pulse Biosciences in a report on Tuesday, July 28th.
Get Our Latest Research Report on PLSE
Insider Activity at Pulse Biosciences
Institutional Trading of Pulse Biosciences
Institutional investors have recently bought and sold shares of the company. Bank of America Corp DE lifted its stake in shares of Pulse Biosciences by 8.2% in the 1st quarter. Bank of America Corp DE now owns 866,061 shares of the company’s stock valued at $18,698,000 after purchasing an additional 65,884 shares during the period. Deutsche Bank AG bought a new stake in Pulse Biosciences in the second quarter worth approximately $687,000. Panoramic Capital LLC acquired a new position in Pulse Biosciences in the second quarter valued at approximately $2,719,000. Legal & General Group Plc acquired a new position in Pulse Biosciences in the second quarter valued at approximately $395,000. Finally, BlackRock Inc. bought a new position in shares of Pulse Biosciences during the 2nd quarter worth approximately $40,672,000. Institutional investors own 76.95% of the company’s stock.
Pulse Biosciences Price Performance
Shares of NASDAQ:PLSE opened at $50.61 on Friday. Pulse Biosciences has a 1 year low of $12.56 and a 1 year high of $58.90. The stock has a market capitalization of $3.58 billion, a price-to-earnings ratio of -42.89 and a beta of 1.63. The company’s 50 day simple moving average is $42.29 and its 200 day simple moving average is $30.01.
Pulse Biosciences (NASDAQ:PLSE – Get Free Report) last released its earnings results on Thursday, August 6th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.07). The business had revenue of $0.43 million during the quarter, compared to the consensus estimate of $0.53 million. Pulse Biosciences had a negative net margin of 6,755.78% and a negative return on equity of 94.42%. As a group, analysts anticipate that Pulse Biosciences will post -1.29 EPS for the current fiscal year.
About Pulse Biosciences
Pulse Biosciences, Inc is a medical technology company developing proprietary bioelectric therapies based on its Nano-Pulse Stimulation technology. The platform delivers ultrashort electrical pulses designed to affect targeted cells while limiting thermal damage to surrounding noncellular tissue.
The company’s primary product is the CellFX System, which is designed to deliver Nano-Pulse Stimulation treatments for certain dermatological conditions. Pulse Biosciences is also developing additional applications for its technology in areas including cardiac procedures and other medical specialties.
Pulse Biosciences was founded in 2014 and is headquartered in Hayward, California.
See Also
- Five stocks we like better than Pulse Biosciences
- Aeluma’s Selloff Could Be Setting Up Its Next Big Move
- Crypto Bill Stalls, Smart Money Calls: Time to Buy the Dip?
- The September Scramble: Find Sanctuary in These 3 Defensive Dividend Stocks
- The Fed’s Rate Hike Could Backfire If Oil Prices Collapse
Receive News & Ratings for Pulse Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulse Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
